- Tech Insights
A product visionary, an innovator, a mission-driven, high-integrity company builder and chief product architect, Lynnet Koh, CEO & Founder, TargaZyme, is driven by a commitment to developing best-in-class medicines to making a life-changing difference for cancer patients and their families, to help employees and partners grow to their very best selves and to build a great company that is built to last.
Lynnet’s qualities include making things happen and being intellectually honest and authentic with a strong sense of curiosity and a desire for continuous improvement. She operates with frugality, agility, tenacity, and creativity – an out-of-the-box thinker with a revolutionary mindset, yet pragmatic, highly practical and street-smart. Big on doing it right the first time and focusing on effective execution with a strong sense of urgency to achieve goals and objectives, Lynnet is a strategic team leader who expects excellence, and continuous improvement, which can be quite exacting on her team relative to paying attention to important details and effective execution.
This steadfast leader leads by example. “If you commit and focus on doing something big, mission-impossible and game-changing, like cancer drugs that can hopefully transform outcomes for cancer patients, you can make it happen no matter what the challenges are.” Lynnet adds, “We can build, from scratch, best-in-class products that transform peoples’ lives around the world even when, to begin with, we knew nothing about the industry when TargaZyme was started, had no staff, no patents, no product data, no funding, nothing other than a dream to transform people’s lives for the better!”
She inspires young entrepreneurs immensely and says, “you can build a company from just an idea to something major, an industry leader making a positive, life-changing impact on cancer patients and their families!” Lynnet sees the pain of cancer patients and their families and is committed to developing breakthrough products that would remove the pain. She has spent years building TargaZyme from just an idea to doing just that. Despite all the naysayers and numerous obstacles, she assembled a talented, experienced and proven medical and scientific team.
She successfully drove the company from the idea stage to positive preclinical validation data, IND enabling activities, positive, human proof-of-concept clinical data, FDA phase 3 Special Protocol Assessment designation, multiple orphan drug designations, 40+ worldwide patents, over $50m of funding and multiple product opportunities that have THE potential to transform the field of cancer medicine and cell therapy and key partnerships.
In focusing the TargaZyme Team on a big mission, Lynnet constantly seeks to transform cancer-patient survival and quality of life, worldwide. Their mission is to harness the cancer patient’s human immune system to fight cancer so that they can render toxic chemotherapeutics, radiation and radical surgery obsolete. There is an element of making change and having an impact that accompanies this mission and Lynnet never lets team members forget the pioneering nature of their work.
“I now define success as having a major impact on people’s lives, for the better, my ability to leave a legacy to this world and make this world truly a better place to live. Since I’ve proven to myself multiple times over that I’m particularly skilled in leading major technology/product innovation and developing best-in-class products that truly transform peoples’ lives around the world, I now regard success in the following way: if through my leadership and my energy, I can help usher a world where, one day, cancer patients can be successfully treated with their own immune system by TargaZyme’s products, without the need for the poison that is chemotherapy/radiation, the potential deformity from radical surgery or the many cancer drugs that may extend life by a few months, but create life-long, major side effects, then we, at TargaZyme, are successful.”
In the next few years, with help from investors, TargaZyme aims to demonstrate, in clinical trials, that their drug candidates can give terminally ill cancer patients a better chance of survival than today's. “In fact, we would like to address cancer and autoimmune disease across-the-board by harnessing the power of the immune system with our platform technology. It is a lofty goal. I suppose that’s what makes it so worth pursuing!”
CEO & Founder
Targazyme Inc. is a San Diego-based, clinical-stage biopharmaceutical company developing novel enzyme-based platform technologies and products to improve clinical efficacy and cost of care outcomes for cell therapy, immunotherapies for autoimmune diseases and cancer, stem cell transplantation, gene therapy and regenerative medicine.